Peter Laing Newsroom

Excivion announces results of an international collaboration evaluating the utility of its novel point-of-care dengue and Zika antibody tests

October 27, 2023

Excivion announces results of an international collaboration evaluating the utility of its novel point-of-care dengue and Zika antibody tests

CAMBRIDGE UK – Excivion Ltd (www.excivion.com), a biotechnology company developing novel vaccines based on its proprietary glycan-cloaking molecular design and adjuvant platforms, today announce...
Read More